Medicofarma Biotech S.A.

What Medicofarma Biotech S.A. does

Medicofarma Biotech S.A. is a Polish biotechnology company headquartered in Warsaw and listed on the Warsaw Stock Exchange NewConnect market (ticker MDB). The company originated within the Medicofarma pharmaceutical group — operating as a pharmaceutical manufacturer since 2005 — and was carved out and rebranded from INBOOK S.A. to Medicofarma Biotech S.A. in 2021 to consolidate the group's R&D activities. It operates R&D centers in Lublin and Poznań, with the Poznań site housed at the Wielkopolska Center for Advanced Technologies under the coordination of Prof. ICHB. The company runs a GMP- and GLP-compliant quality system and holds a manufacturing authorization from the Chief Pharmaceutical Inspector (permit 259/0611/20).

The company's portfolio spans contract laboratory services, in-vitro diagnostics, oncology research platforms, therapeutic pipeline projects, functional food and dermocosmetics. Core scientific platforms include CANCER PRINT (3D bioprinting of patient-derived breast, ovarian and brain tumor tissue models), BREAST/OVARY ATN (tenascin-C inhibition therapy), TenasiRNA (lipid-nanoparticle RNA therapy targeting cancer stem cells), TymSTOP (thymidylate synthase/Wnt pathway inhibitors), and the MediPAN family of RT-PCR COVID-19 tests co-developed with ICHB PAN and manufactured via Polpharma, Future Synthesis and A&A Biotechnology. The company also distributes OTC products, dietary supplements and 4-N-furfurylcytosine-based anti-aging dermocosmetics under an exclusive license (US patent 8,404,660B2) from PAS Institute of Bioorganic Chemistry. R&D funding has historically been supported by EU Operational Programme Smart Growth 2014-2020 (PLN 7.07M for the VITAMA R&D Center) and NCBR NUTRITECH (PLN 5.31M for the IBShot functional beverage project).

The business model combines four revenue streams: (1) contract R&D and analytical laboratory services for pharmaceutical, cosmetic, food processing and chemical clients; (2) product sales of OTC pharmaceuticals, dietary supplements, dermocosmetics and COVID-19 diagnostic kits; (3) licensing royalties from the 4-N-furfurylcytosine anti-aging molecule; and (4) non-dilutive EU/NCBR grant funding. Go-to-market is sales-led and primarily domestic (Poland), with stated intent to expand into foreign OTC and supplement markets via direct outreach. Customer segments are diversified across four B2B verticals but no individual enterprise customers are publicly named. The company operates through a very lean team of 8 employees, 50% of whom hold PhDs, and is governed by a board combining scientific founders with executives drawn from P&G, US Pharmacia, Valeant and major Polish banks.

Name

Medicofarma Biotech S.A.

Legal name

Medicofarma Biotech S.A.

Website

https://medicofarmabiotech.pl

Company type

Public

Founded year

2005

Operating status

Operating

Headcount range

1–10 employees

Short description

Polish biotech (NewConnect-listed, ticker MDB) operating contract R&D laboratories and developing oncology therapeutics, RT-PCR diagnostics, functional foods and dermocosmetics for pharmaceutical, cosmetic, food and chemical clients.

Ownership category

akta.pro rank

Product category

Biotechnology Research and Development

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835), Services-Testing Laboratories (8734)

akta.pro primary industry

CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)

akta.pro secondary industries

mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC), GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification) (HLAGAGAL), Toxicology & Safety Assessment CROs (GLP) (HLAGAAAC)

Keywords

• Biotechnology research
• Contract research services
• RT-PCR diagnostic tests
• Pharmaceutical product development
• Functional food development

Headquarters

HQ city

Warsaw

HQ country

Poland

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. R&D Contract Services: Contract laboratory services for pharmaceutical, cosmetic, food processing, and chemical companies including research and development and routine analyses
2. Product Sales: Sales of medicinal products, medical devices, dietary supplements, and COVID-19 test kits
3. Licensing Royalties: Revenue from exclusive license for anti-aging formulation with 4-N-furfurylcytosine molecule
4. Grant Funding: EU and government subsidies for R&D projects including EU Operational Programme Smart Growth 2014-2020 and NCBR NUTRITECH programme

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

Medicofarma Biotech operates as a contract research laboratory providing R&D, analytical testing, method development/validation/transfer, and preformulation services to pharmaceutical, cosmetic, food processing and chemical companies under GMP/GLP standards. It also develops and commercializes its own portfolio of COVID-19 RT-PCR diagnostic kits, oncology research platforms, pipeline therapeutics, functional foods and anti-aging dermocosmetics, leveraging a strategic research partnership with the Polish Academy of Sciences.

Product overview

Medicofarma Biotech S.A. is a biotech company listed on NewConnect offering an integrated portfolio of COVID-19 diagnostic tests (MediPAN product line with five generations), cancer research platforms (CANCER PRINT 3D bioprinting and BREAST/OVARY ATN therapy), pipeline therapeutics (TenasiRNA, TymSTOP, FITOMOLEKUŁY, AdaptogenPRO), functional food (IBShot), and dermocosmetics (4-N-furfurylcytosine). The company operates R&D centers in Lublin and Poznań, providing contract research services including analytical testing and preformulation under GMP/GLP standards.

Differentiator

Problem solved

Functional benefit

Brands

• MediPAN COVID SARS-CoV-2: First Polish genetic test kit for detecting SARS-CoV-2 virus using RT-PCR technology
• MediPAN FAST COVID + FLU
• TenasiRNA
• TymSTOP
• IBShot

Products and services

• MediPAN COVID SARS-CoV-2

Quantifiable outcome

• Virus detection sensitivity over 99% for COVID-19 tests
• +1 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Uniwersytet Przyrodniczy w Poznaniu (University of Life Sciences in Poznań)coreStrategic or Co-development Partner · 20 October 2023Consortium partner in NUTRITECH project for developing vitamin drink enriched with compounds of natural origin for irritable bowel syndrome treatment. Medicofarma Biotech is part of the consortium including Medicofarma S.A. and the university.
• Institute of Bioorganic Chemistry of the Polish Academy of Sciences (ICHB PAN)coreStrategic or Co-development Partner · 1 January 2017Long-term partnership initiated in 2017 for R&D infrastructure establishment. Collaboration includes epigenetic research on DNA modifications, development of 3D bioprinting technology, and joint development of COVID-19 test kits (MediPAN series). Medicofarma acquired exclusive license for 4-N-furfurylcytosine anti-aging molecule from this partner.
• Maria Curie-Skłodowska University in LublinminorStrategic or Co-development PartnerFramework partnership agreements for research collaboration including development of imprinted polymers for specific capture of medical substance molecules and polymers for immobilizing and controlled release of medical substances.
• Łódź University of TechnologyminorStrategic or Co-development PartnerCollaboration on use of hydrodynamic cavitation for obtaining plant-origin extracts and mesoporous sorbents for imprinting medical substance molecules.
• Medical University of LublinminorStrategic or Co-development PartnerJoint development of probiotic preparations with plant extracts for digestive health and oral cavity infection prevention and treatment.
• Adam Mickiewicz University in PoznańminorStrategic or Co-development PartnerRental agreement for laboratory space at the Wielkopolska Advanced Technologies Center. Collaboration on innovative oncology drug development and post-COVID-19 therapy research.
• PolpharmaminorStrategic or Co-development PartnerManufacturing partner for COVID-19 test kit production and market implementation alongside Medicofarma.

Scale indicators5 records

Recent moves9 records

Expansion highlights5 records

Direct peers

• Selvita S.A. Polish contract research organization offering drug discovery, preclinical services, and integrated chemistry/biology R&D to pharma clients. Directly comparable as a Polish-listed CRO with both services and proprietary therapeutic development.
• Genomtec S.A. Polish molecular diagnostics company developing rapid RT-PCR and isothermal diagnostic platforms. Directly comparable as a Polish-listed diagnostics developer using nucleic-acid amplification technology.
• OncoArendi Therapeutics S.A. Polish clinical-stage biotech developing small-molecule therapies for oncology and inflammatory diseases. Comparable as a Polish-listed biotech pursuing novel mechanism therapeutics with academic roots.
• Synektik S.A. Polish medical technology company providing radiopharmaceuticals, molecular diagnostics, and IT systems for healthcare. Comparable as a Polish-listed diagnostics/medtech company with proprietary product portfolio.
• Ryvu Therapeutics S.A. Polish clinical-stage oncology biotech developing small-molecule therapies for hematologic malignancies and solid tumors. Comparable as a Polish-listed small-cap biotech pursuing differentiated mechanism oncology assets.
• Celon Pharma S.A. Polish integrated pharmaceutical company with proprietary drug development across oncology, metabolic, and respiratory indications, plus contract manufacturing. Comparable as a Polish-listed pharma with internal R&D pipeline.
• Pure Biologics S.A. Polish biotech developing therapeutic antibodies and aptamer platforms, plus research reagents. Comparable as a small-cap Polish-listed biotech with proprietary platform technologies and limited headcount.
• Scope Fluidics S.A. Polish biotech holding company focused on rapid molecular diagnostics and microfluidic systems. Comparable as a Polish-listed small-cap diagnostics innovator with proprietary platform technology.
• Mabion S.A. Polish biotech/CDMO focused on biologics development and GMP manufacturing for third-party clients. Comparable as a small-cap Polish-listed biopharma combining contract manufacturing services with proprietary biologics pipeline.

Regional players

• BIOMED Lublin WSiI S.A. Polish pharmaceutical manufacturer producing vaccines, blood products, and generics with proprietary R&D. Comparable as a Poland-based pharma combining contract/proprietary manufacturing with drug development, though at a larger scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/medicofarma-biotech-s.a.

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medicofarma Biotech S.A.